Favipiravir (T-705) protects against Nipah virus infection in the hamster model
Open Access
- 15 May 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 8 (1), 1-11
- https://doi.org/10.1038/s41598-018-25780-3
Abstract
Nipah and Hendra viruses are recently emerged bat-borne paramyxoviruses (genus Henipavirus) causing severe encephalitis and respiratory disease in humans with fatality rates ranging from 40–75%. Despite the severe pathogenicity of these viruses and their pandemic potential, no therapeutics or vaccines are currently approved for use in humans. Favipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe. Favipiravir has demonstrated efficacy against a broad spectrum of RNA viruses, including members of the Paramyxoviridae, Filoviridae, Arenaviridae families, and the Bunyavirales order. We now demonstrate that favipiravir has potent antiviral activity against henipaviruses. In vitro, favipiravir inhibited Nipah and Hendra virus replication and transcription at micromolar concentrations. In the Syrian hamster model, either twice daily oral or once daily subcutaneous administration of favipiravir for 14 days fully protected animals challenged with a lethal dose of Nipah virus. This first successful treatment of henipavirus infection in vivo with a small molecule drug suggests that favipiravir should be further evaluated as an antiviral treatment option for henipavirus infections.Keywords
This publication has 55 references indexed in Scilit:
- A Neutralizing Human Monoclonal Antibody Protects African Green Monkeys from Hendra Virus ChallengeScience Translational Medicine, 2011
- Clinical Outcome of Henipavirus Infection in Hamsters Is Determined by the Route and Dose of InfectionJournal of Virology, 2011
- A Novel Model of Lethal Hendra Virus Infection in African Green Monkeys and the Effectiveness of Ribavirin TreatmentJournal of Virology, 2010
- T-705 (favipiravir) activity against lethal H5N1 influenza A virusesProceedings of the National Academy of Sciences of the United States of America, 2009
- Chloroquine Administration Does Not Prevent Nipah Virus Infection and Disease in FerretsJournal of Virology, 2009
- Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infectionJournal of General Virology, 2009
- Henipavirus RNA in African BatsPLOS ONE, 2009
- Treatment of Late Stage Disease in a Model of Arenaviral Hemorrhagic Fever: T-705 Efficacy and Reduced Toxicity Suggests an Alternative to RibavirinPLOS ONE, 2008
- Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in MiceAntimicrobial Agents and Chemotherapy, 2007
- Poly(I)-Poly(C 12 U) but Not Ribavirin Prevents Death in a Hamster Model of Nipah Virus InfectionAntimicrobial Agents and Chemotherapy, 2006